KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares Outstanding
Ratios

Organon (OGN) R&D In Process (2021 - 2025)

Organon has reported R&D In Process over the past 5 years, most recently at $6.0 million for Q1 2025.

  • For Q1 2025, R&D In Process fell 60.0% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $6.0 million, down 92.59%, while the annual FY2025 figure was $6.0 million, 92.59% down from the prior year.
  • R&D In Process for Q1 2025 was $6.0 million at Organon, down from $51.0 million in the prior quarter.
  • Over five years, R&D In Process peaked at $97.0 million in Q2 2022 and troughed at $6.0 million in Q1 2025.
  • A 5-year average of $34.0 million and a median of $15.0 million in 2024 define the central range for R&D In Process.
  • Biggest five-year swings in R&D In Process: tumbled 60.0% in 2022 and later surged 87.5% in 2024.
  • Year by year, R&D In Process stood at $79.0 million in 2021, then plummeted by 87.34% to $10.0 million in 2022, then fell by 20.0% to $8.0 million in 2023, then skyrocketed by 537.5% to $51.0 million in 2024, then tumbled by 88.24% to $6.0 million in 2025.
  • Business Quant data shows R&D In Process for OGN at $6.0 million in Q1 2025, $51.0 million in Q3 2024, and $15.0 million in Q2 2024.